Quantcast

USPTO Grants a New Inhaler Patent to Hovione

April 7, 2014

LISBON, Portugal, April 7, 2014 /PRNewswire/ –

Hovione announced today that the United States Patent and Trademark Office (USPTO) has
granted a patent for a capsule-based, low-cost dry powder inhaler (DPI) to Hovione. This
happened less than three years after the patent was filed and after just one Office Action
- unusual speed for an inhaler application.

Hovione have designed this inhaler to have just two operating components, thereby
achieving significant cost savings and giving the patient unprecedented ease of use. In
use, the patient just needs two steps before inhaling. In terms of delivery performance,
lung fractions in excess of 70% have been achieved. This makes this inhaler highly suited
for inhalation applications where minimal training of patients is desirable and has the
versatility to treat most pulmonary diseases, including asthma, COPD as well as infection,
which typically requires very large doses.

XCaps follows on the heels of another successful Hovione DPI, TwinCaps(R), which was
developed for the delivery of the anti-viral drug, laninamivir, to treat influenza and is
now approved in Japan and marketed by licensee Daiichi-Sankyo as part of their Inavir(R)
product. Hovione inhalers are offered for licensing, together with formulation and
particle engineering services on a fee for service basis. The company has also developed a
line of inhalation-grade APIs, including fluticasone, salmeterol, mometasone and
tiotropium.

Peter Villax, Vice-President and co-inventor of the device, said “We give our
customers an edge in speed of development because we are perhaps the only independent
company developing DPIs with expertise in every aspect of the inhaled drug development
process. This patent grant in the US within 30 months of initial filing, underpins
Hovione’s capabilities in innovation and intellectual property management, to successfully
design, develop and deliver innovative products.”

“The XCaps addresses a gap for a simple, easy to use, cost effective, multiple use,
capsule based inhalation device. This allows our business partners to take advantage of
additional patent protection for their inhalation drug product and effective drug product
life cycle management” said Goncalo Andrade, Business Development Manager.

Hovione is currently executing inhaled drug development projects for 5 pharmaceutical
companies, involving API process development, particle engineering, formulation and
clinical supplies and is looking for partners willing to incorporate Hovione inhalers into
their inhalation drug product development.

About Hovione. Hovione is an international company with over 50 years’ experience in
Active Pharmaceutical Ingredient development and compliant manufacture. With four FDA
inspected sites in the U.S., China, Ireland, and Portugal, the company focuses on the most
demanding customers, in the most regulated markets. The company also offers branded
pharmaceutical customers services for the development and compliant manufacture of
innovative new drugs, is able to support highly potent compounds and offers all customers
proprietary product development and licensing opportunities for drug products. In the
inhalation area, Hovione is the only independent company offering such a broad range of
services.

More about XCaps at http://www.hovione.com/inhale

        Contacts at Hovione:
        Goncalo Andrade, PhD MBA
        Business Development Manager
        gandrade@hovione.com
        +351-219-847-619

        Isabel Pina
        Director Corporate Communications
        ipina@hovione.com
        +351-21-982-9362

http://www.hovione.com

SOURCE Hovione


Source: PR Newswire



comments powered by Disqus